---
figid: PMC5418169__40169_2017_147_Fig1_HTML
figtitle: Negative feedback regulates the RAS/MAPK pathway
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC5418169
filename: 40169_2017_147_Fig1_HTML.jpg
figlink: /pmc/articles/PMC5418169/figure/Fig1/
number: F1
caption: Negative feedback regulates the RAS/MAPK pathway. Although MAPK signaling
  was previously considered linear, autoregulatory negative feedback loops precisely
  control signaling output. MEK inhibitors reduce activity of ERK1 and ERK2 and then
  relieve the feedback inhibition of RAF, resulting in enhancement of RAF kinase activity.
  Likewise, ETS1-targeted therapy may activate ERK1 and ERK2 by inhibiting DUSP6,
  which is an ETS1 transcriptional target
papertitle: 'ETS-targeted therapy: can it substitute for MEK inhibitors?.'
reftext: Osamu Tetsu, et al. Clin Transl Med. 2017;6:16.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9457617
figid_alias: PMC5418169__F1
figtype: Figure
redirect_from: /figures/PMC5418169__F1
ndex: 7bfcbd1a-deb1-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5418169__40169_2017_147_Fig1_HTML.html
  '@type': Dataset
  description: Negative feedback regulates the RAS/MAPK pathway. Although MAPK signaling
    was previously considered linear, autoregulatory negative feedback loops precisely
    control signaling output. MEK inhibitors reduce activity of ERK1 and ERK2 and
    then relieve the feedback inhibition of RAF, resulting in enhancement of RAF kinase
    activity. Likewise, ETS1-targeted therapy may activate ERK1 and ERK2 by inhibiting
    DUSP6, which is an ETS1 transcriptional target
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Sos
  - ras
  - Ras64B
  - Ras85D
  - Raf
  - Dsor1
  - rl
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - XYLT2
  - SOS1
  - SOS2
  - KRAS
  - HRAS
  - NRAS
  - MTG1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K1
  - MAP2K2
  - MAPK3
  - MAPK1
  - ETS1
  - DUSP6
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
---
